Estamos realizando la búsqueda. Por favor, espere...
1575
37
170
28863
4397
2595
347
362
Abstract: Objective: Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients. Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA). Results: There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028). Conclusion: We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.
Fuente: Acta reumatológica portuguesa, 2020, 45, 259-264
Editorial: Sociedade Portuguesa de Reumatologia
Año de publicación: 2020
Nº de páginas: 6
Tipo de publicación: Artículo de Revista
ISSN: 0303-464X
Consultar en UCrea
CANTERO-NIETO, L.
ALVAREZ-CIENFUEGOS, A.
GARCÍA-GÓMEZ, J. A.
MARTIN, J.
MIGUEL ANGEL GONZALEZ-GAY MANTECON
ORTEGO-CENTENO, N.
Volver